US-based life sciences and diagnostics company Revvity announced that its subsidiary Euroimmun has launched the Anti-Measles Virus ELISA 2.0 (IgG) assay.
Anti-Measles Virus ELISA 2.0 (IgG) is a CE-marked assay designed to support the diagnosis of measles virus infections and determine immune status.
Euroimmun is a German company that manufactures medical laboratory diagnostics.
The new assay expands Euroimmun’s portfolio of serological infection diagnostics with validation for dried blood spots (DBS) as sample material, alongside serum and plasma.
Euroimmun chief scientific officer Lars Komorowski said: “Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution.”
The use of DBS in diagnostics offers a minimally invasive method, requiring only capillary blood droplets, and enhances testing accessibility and efficiency.
Also, the Anti-Measles Virus ELISA 2.0 (IgG) assay can be processed manually or automatically, using Euroimmun’s scalable solutions for DBS processing and ELISA.
The samples are collected from the fingertip and sent to diagnostic laboratories for analysis, facilitating routine testing and use in areas lacking developed medical infrastructure.
Revvity provides life science solutions across discovery, development, diagnosis, and cure.
The company is focused on translational multi-omics technologies, biomarker identification, and imaging, among others, and serves a wide range of customers.
It serves pharmaceutical and biotech companies, diagnostic labs, academia, and governments, across more than 160 countries.
